Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1650-1652

  Jander, Sebastian ^a   Turowski, Bernd ^b   Kieseier, Bernd C ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Orthopedic Surgery   (Germany)

Author keywords

fingolimod; MRI; Multiple sclerosis; natalizumab; tumefactive demyelination

Indexed keywords

FINGOLIMOD; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NATALIZUMAB; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANALOGS AND DERIVATIVES; BRAIN; CASE REPORT; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG SUBSTITUTION; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868018268     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512463768     Document Type: Article

References (7)

1. Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008 ; 131: 1759-1775 (Pubitemid 351957454)
2. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
3. Kleinschmidt-Demasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012 ; 71: 604-617
4. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 ; 68: 186-191
5. Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?. Neurology. 2012 ; 78: 928-30
6. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 ; 18: 113-115
7. Leypoldt F, Münchau A, Moeller F, et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology. 2009 ; 72: 1022-1024